The Impact of MRI on Genitourinary and Gastrointestinal Toxicity after Radiation Therapy

Poster Feb 21, 2017

View Poster

Kyle Kilinski; Arash Naghavi, MD; Yazan Abuodeh, MD; Michelle Echevarria, MD2; Nainesh Parikh, MD; Kenneth Gage, MD, PhD; Kosj Yamoah, MD, PhD

MRI has several advantages relative to other imaging modalities in evaluating, diagnosing, and planning treatment for prostate cancer. However, it is rarely ordered for localized disease. While the diagnostic abilities have been studied, little has been done to associate clinical outcomes with prostate cancer patients who received MRI. The study evaluates the effect of pre-treatment MRI on genitourinary (GU) and gastrointestinal (GI) toxicity in prostate cancer patients who received definitive radiation treatment.

We retrospectively analyzed all prostate cancer patients who underwent definitive radiation treatment at our facility between January 01, 1999 and July 31, 2014. All patients who underwent MRI of the pelvis or prostate within 5 years prior to treatment were included in the MRI cohort. The American Urological Symptom Score (AUA) and Rectal Assessment Scale (RAS) were used to measure GU and GI toxicity, respectively. We compared the toxicity profile of patients in our MRI cohort to a comparable cohort of patients who did not receive pre-treatment MRI.

1085 patients (211 with MRI) were analyzed. Median follow-up was 30 months. Mean increase from baseline in AUA scores at 6 months was 3.58 for the MRI cohort and 5.04 for the comparison cohort (p = 0.017). RAS scores were not significantly different between the MRI and comparison cohorts at 6 months (mean increase: 0.62 vs. 0.77, p = 0.662). AUA scores returned to baseline after 6 months in the MRI cohort and after 12 months in the comparison cohort. RAS scores returned to baseline after 12 months in the MRI cohort but never returned to baseline in the comparison cohort. Biochemical failure rates were not significantly different between the MRI cohort and comparison cohort (86.3% vs. 91.1%, p = 0.083).

Pre-treatment MRI was associated with significantly less GU and GI toxicity. These results may be influenced by more advanced disease and higher use of hormonal therapy in the MRI cohort. Future prospective studies in a risk-matched cohort are required to validate these findings.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License

View Poster

OTHER POSTERS

Interrogation and Modulation of the Immunosuppressive Activity of Human TAM-Like Macrophages Using In Vitro Cultures

Poster

Tumor associated macrophages (TAMs) can facilitate the proliferation of tumor cells and are able to suppress anti-tumor immune responses within the tumor microenvironment, making them a highly attractive target for the development of innovative cancer immunotherapies.

Meet Your Separation Needs With Thermo Scientific

Poster

Download this poster to learn more about chromatography separations.

5 Steps Rare Events Analysis With Flow Cytometry

Poster

Download this poster to discover the five key steps in applying flow cytometry for rare events analysis, helping you to ensure that your results and data are accurate, thorough and reproducible.

Like what you just read? You can find similar content on the communities below.

Analysis & Separations Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free